Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody

Catalog No. ABIN7200668

This Mouse Monoclonal antibody specifically detects PDCD1 (Pembrolizumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody (ABIN7200668)

Target: PDCD1 (Pembrolizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-PDCD1 (Pembrolizumab Biosimilar) Antibody

Purpose: Pembrolizumab Biosimilar, Human PD-1 Monoclonal Antibody

Specificity: The in vivo grade pembrolizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1 or PD1), antagonizing its interaction with its known ligands PD-L1 or PDL1, and PD-L2 or PDL2.

Characteristics: Recombinant Humanized IgG4 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab biosimilar was produced in the pembrolizumab biosimilar CHO stable cell line.

Isotype: IgG4 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pembrolizumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for PDCD1 (Pembrolizumab Biosimilar)

Target: PDCD1 (Pembrolizumab Biosimilar)

Target Type: Biosimilar

Background: What is Pembrolizumab biosimilar research grade? Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. Pembrolizumab Biosimilar uses the same protein sequences as the therapeutic antibody pembrolizumab.